课题基金 / 基金详情

Impact of Fc N-glycan structure on HIV-specific antibody functions

Impact of Fc N-glycan structure on HIV-specific antibody functions
Fc N-聚糖结构对 HIV 特异性抗体功能的影响
批准号:
9322012
负责人:
Donald L. Jarvis
金额:
$74.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-01 至 2020-07-31

项目摘要

项目成果

Donald L. Jarvis的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): HIV infections have a significant worldwide impact on human health. Despite our inability to develop a highly effective vaccine to date, it is still widey believed that vaccination could control the HIV pandemic. A highly effective vaccine might induce broadly neutralizing antibodies (bNAbs) that can neutralize diverse HIV isolates, analogous to those produced by some patients with long-term control over HIV infection1,2. This vaccine would probably also induce non-neutralizing antibodies (nNAbs) with potent effector functions that can reduce the risk of HIV infection, analogous to those produced by some subjects in the RV144 vaccine trial3-5. In parallel with vaccine development, it is thought that we can manufacture and passively administer bNAbs and/or nNAbs for post-exposure prophylaxis or as an adjunct to antiretroviral therapy, particularly against resistant viruses. The ability to broadly neutralize different HIV variants and induce potent effector functions are both critically important factors in the ability of HIV-specific antibodies (HIV-Abs) to control infection6. In tur, the potency of Fc receptor (FcR)-mediated effector functions is known to depend upon IgG N-glycan structure7. Unfortunately, we do not have comprehensive information on the impact of Fc glycosylation on relevant HIV-Ab functions in the overall immune response to HIV infection. Clearly, some recent studies have broken ground, provided important insights, and stimulated great interest in this area8-12. But, they also demonstrated the need for further analysis of a broader selection of glycoforms, of the impact of N-glycan structure on the ability of HIV- Abs to block mucosal transmission, and of the overall protective efficacy of different glycoforms in preclinical animal models permissive for HIV infection. We propose to achieve these goals in a more comprehensive analysis of the impact of N-glycan structure on the in vitro and in vivo functions of HIV-Abs in the overall immune response to HIV infection. We will use a VRC01 and A32 as models for functional glycomic studies designed to examine the broadest selection of glycoforms in the broadest set of assays used in any study reported to date. We will assess the impact of eight distinct N-glycosylation profiles on VRC01 and A32 functions, including viral neutralization (VRC01) and effector functions (both HIV-Abs). We also will assess the overall abilities of a selected subset of different VRC-01 and/or A32 glycoforms to protect against mucosal transmission of HIV in the hu-BLT mouse, a preclinical animal model system. The results will reveal N-glycan- based mechanisms modulating the immune responses driven by two functionally distinct HIV-Abs and identify one or more specific glycoforms as optimal targets for induction by an HIV vaccine and/or for recombinant manufacturing in advance of human therapeutic applications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    8663969
  • 项目类别:
  • 资助金额:
    $30.64万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    9070005
  • 项目类别:
  • 资助金额:
    $30.95万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    8847411
  • 项目类别:
  • 资助金额:
    $30.95万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
Elucidating the cellular mechanisms of prion propagation and clearance for devisi
  • 批准号:
    8465922
  • 项目类别:
  • 资助金额:
    $29.87万
  • 财政年份:
    2012
  • 负责人:
    Donald L. Jarvis
  • 依托单位:
海外基金